Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
A normal IV bag takes about 30-60 minutes to complete
Key Episode Timestamps 00:00:01 Introduction and Participant Backgrounds 00:01:18 Overview of MASH and Insulin Resistance 00:03:28 Phase 2 and Phase 3 Trials of Semaglutide 00:07:23 Significant Findings and Clinical Implications 00:09:44 Challenges and Future Directions 00:14:50 Mechanism of Action and Weight Loss 00:17:39 Data on Weight Loss and Liver Improvement 00:20:42 Potential for FDA Approval and Future Studies 00:25:04 Conclusion and Final Thoughts In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new Phase 3 data from the ESSENCE trial examining semaglutide 2.4 mg (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis
What Happens When You Miss A Dose Or Pause Treatment Life happens, and you might occasionally have missed doses or need to pause treatment
While these anecdotal accounts offer valuable insights, it's vital to remember that individual experiences can differ greatly
To minimize side effects, we start with a low dose and gradually increase it based on your response and the latest clinical guidelines
For example, it may enhance the effects of some chemotherapy drugs or interact with medications that affect liver function
